Soft start masks structural challenges: margins compressed, US flat, guidance credibility at risk

Revenue +2.1% YoY, PAT -4.6% YoY, EBITDA margin 27% vs 30% prior year

Incremental reversal on top of regular quarterly reversals suggests ongoing revenue recognition volatility; no disclosure of normalized run rate

Pharma API (60% of revenue) declined 7% YoY; international sales fell 14% YoY in Q1; management deflected on sequential comparisons

US business flat/declining for 8-9 years per analyst query; industry grows 6-7%; no revenue yet from branding shift; geopolitical and tariff headwinds cited

FY26 delivered 20%+ growth (multiple quarters); Q1 FY27 only 2% YoY. Management blamed temporary factors (price increases, customer inventory issues, geopolitical) but offered no new guidance timeline.

27% vs 30% Q1 FY26 and 31% Q4 FY26. 300 bps YoY deterioration attributed to power/fuel costs and sales mix; recovery to 30% claimed but not committed for specific quarter.

Shifting from commodity supply to branded ingredient positioning. Execution unclear; international Human Healthcare sales fell 14% YoY despite realization improvement. No revenue uplift yet from branding.

₹123 Cr CapEx for FY27 (vs historical lower run rate); fermentation utilization at 70-75% (up from stated 55-60%). Concrete but execution-dependent.

JC Biotech acquisition 4.28% stake for ₹79.79 Cr to 100% ownership; evoxx loss-making (₹18 Cr negative PAT Q1); SciTech improved. Portfolio quality mixed.

Geopolitical issues, tariff effects, hiring challenges, business model change (branding). Expect 8-10% growth going forward. Will continue fermentation in India; alternate sourcing requires high capex; focus on productivity improvement and R&D.

Yes, we should grow double digits. ₹10 Cr incremental reversal lost; if added back ₹200 Cr = ~8% growth. Costs will improve with operational efficiency. Confident on guidance numbers shared in past.

Staying B2B but labeling products with company name makes it sticky business; customers can't switch easily. Realization improved vs Q4/Q1 last year.

Material in transit not yet delivered to customer; revenue recognition happens on delivery. Incremental by ₹10 Cr this quarter; should normalize as goods arrive.

Working on food areas, protein solubilization, other industries. Don't track product-by-product sales; 15-20 molecules in pipeline; few commercialize each quarter.

₹123 Cr for FY27 (₹20 Cr stretches Q2). ₹20 Cr maintenance, ₹50 Cr R&D (work in progress, functional next quarter), balance growth. At 70-75% utilization; will take call Q2 on further expansion.

Yes, expect recovery to 30% EBITDA. Inventory ₹190 Cr, receivables ₹131 Cr, payables ₹41 Cr = ₹280 Cr WC; cycle 125-138 days.

India: ₹580 Cr Q1 vs ₹699 Q4 and ₹659 Q1 FY26. International: ₹559 Cr vs ₹582 Q4 and ₹562 Q1 FY26.

Don't compare quarter-to-quarter; business has 70-80% constant customers, 20-30% churn. Pharma side was slow this quarter too. Expect strong momentum next quarter; inventory and customer-level issues complicate QoQ.

EFSA approval still pending (since 2014, no timeline). Don't track product-level sales; always 15-20 molecules in pipeline. Expanding biocatalysis, animal feed, ruminant, detergent areas.

Sugar mgmt: US patent granted, big market (GLP-1 connection), working on branding. Protein hydrolysis: some sales started this quarter. Bioenergy: no revenue yet, still in development; prioritize core areas.

Management claims confidence in 'guidance numbers shared in past' but Q1 delivery (2% YoY) contradicts aspiration. If ₹10 Cr reversal added back, Q1 is ~8% adjusted. Full-year guidance hinges on Q2-Q4 momentum (implied ~15%+ needed for double-digit). No formal numeric FY27 target disclosed.

Expects energy/power costs to normalize; operational efficiencies to drive improvement. Prior baseline 30-31% (Q1 FY26, Q4 FY26). No specific quarter called out for 30% achievement.

Breakdown: ₹20 Cr maintenance, ₹50 Cr R&D (work in progress, functional next quarter), balance (~₹53 Cr) growth. Decision on further expansion CapEx deferred to Q2.

US enzyme market growing 6-7% YoY; AET flat or declining for 9 years. International Human Healthcare -14% YoY Q1. US expected 8-10% growth but track record poor; branding pivot unproven.

Pharma API (60% of Human Healthcare revenue, ~36% of total) fell 7% YoY. No new product launches disclosed to offset. Serratiopeptidase ban rumors (FDC combination impact ~1% per mgmt) suggest regulatory/competitive pressure.

INR 10 Cr incremental sales reversal in Q1 (on top of regular quarterly reversals) due to revenue recognition on shipment vs delivery. Management claims one-time but signals revenue timing risk. Revenue recognized when goods shipped but withheld when transit.

Q1 EBITDA margin 27% vs 30% Q1 FY26 and 31% Q4 FY26 (300 bps YoY erosion). Blamed on elevated power/fuel costs, sales mix shift. Recovery to 30% claimed but no timeline; if energy costs remain elevated or volume growth doesn't materialize, margins stay under pressure.

₹123 Cr CapEx for FY27 (₹50 Cr R&D facility, balance growth) is aggressive vs historical spend. R&D facility to be functional H2 FY27 but new product commercialization timeline unclear. Growth CapEx payback contingent on volume growth trajectory (currently weak at 2% YoY).